Skip to content
Search

Latest Stories

Children born to men taking valproate at increased risk of neurodevelopmental disorders

Children born to men taking valproate at increased risk of neurodevelopmental disorders

Patients should not stop taking their anti-seizure medicine without advice from their healthcare professional

The Medicine and Healthcare products Regulatory Agency (MHRA) has cautioned men on valproate to talk to their healthcare professional about their treatment, if they want to start a family in the next year.


The warning came after a new study, commissioned by the European Medicines Agency, suggested that children fathered by men who took the anti-seizure medicine in the three months prior to conception may be at higher risk of developing neurodevelopmental disorders.

Around five in 100 children born to fathers treated with valproate around conception were diagnosed with a neurodevelopmental disorder, compared to three in 100 children whose fathers were taking other antiseizure medicines (lamotrigine or levetiracetam).

However, the risk is believed to be much smaller than the risk associated with valproate in pregnancy.

The revised study results are being reviewed by the MHRA as part of their ongoing monitoring of the safety of valproate.

The health regulator said it will be seeking independent expert advice from the Commission on Human Medicines, and any further guidance will be communicated to patients and healthcare professionals.

In November 2023, the MHRA issued a Valproate National Patient Safety Alert warning that the drug may cause serious harm to the baby, if taken during pregnancy, and lead to impaired fertility in males.

Health organisations were also instructed to prepare for new regulatory measures to reduce the serious harms of valproate.

As per the new measures, expected to be introduced later in January, valproate must not be started in new patients (male or female) younger than 55 years, unless “there is no other effective or tolerated treatment, or there are compelling reasons that the reproductive risks do not apply.”

Patients are informed that they should not stop taking valproate without advice from their healthcare professional, and those who have concerns are encouraged to talk to their doctor.

More For You

Lack of funding deters NI pharmacy contractors from expanding portfolio

W G Hamilton Pharmacy is the third pharmacy in Northern Ireland to be recently sold to first-time buyers.

Pharmacy ownership trends shift in Northern Ireland due to funding gap

An increasing number of pharmacies in Northern Ireland are being acquired by first-time buyers, as existing contractors and groups pull back from expanding their portfolios amid ongoing funding pressures, according to specialist business property adviser Christie & Co.

Among the most recent sales is W G Hamilton Pharmacy, a busy community pharmacy in Ballysillan, North Belfast.

Keep ReadingShow less
RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less